Accessibility Menu
Alpine Immune Sciences logo

Alpine Immune Sciences(NASDAQ) ALPN

This security has been delisted. This page is retained for historical reference.

Alpine Immune Sciences last closing stock price
MetricPriceDate
Last closeUSD 64.972024-05-17
Alpine Immune Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.05%USD 64.942024-05-10
1 month+0.79%USD 64.462024-04-17
3 month+107.84%USD 31.262024-02-16
Year to date+240.87%USD 19.062023-12-29
1 year+655.47%USD 8.602023-05-18
3 year+373.2%USD 13.732021-05-18
5 year+991.93%USD 5.952019-05-17
Since inception+580.31%USD 9.552017-07-25

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

ALPN Financials

Key Financial Metrics (TTM)

Gross Margin

-37.41%

Operating Margin

-75.16%

Net Income Margin

-54.66%

Return on Equity

-12.69%

Return on Capital

-13.10%

Return on Assets

-8.47%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$33.63M

Operating Income

-$51.35M

EBITDA

-$41.10M

Operating Cash Flow

-$80.55M

Capital Expenditure

-$413.00K

Free Cash Flow

-$80.96M

Cash & ST Invst.

$305.66M

Total Debt

$9.66M

Alpine Immune Sciences Performance Analysis

Alpine Immune Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 23,443,000N/A
20222022-12-31USD 30,064,00028.2%
20232023-12-31USD 58,876,00095.8%
Alpine Immune Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30-8.5%
Q32023-09-3016.9%
Q42023-12-31207.2%
Q12024-03-31-77.2%
Alpine Immune Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.98N/A
20222022-12-31USD -1.73-12.6%
20232023-12-31USD -0.64-62.7%
Alpine Immune Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30-17.4%
Q32023-09-3011.1%
Q42023-12-31141.2%
Q12024-03-31-383.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2024YOY CHG

Revenue

$7.03M

-25.1%

Gross Profit

-$15.43M

-266.8%

Gross Margin

-2.19%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

142

N/A

Net Income

-$17.92M

-62.7%

EBITDA

-$22.55M

-108.8%

Quarterly Fundamentals

Name
Q1 2024YOY CHG

Total Cash

$305.66M

+56.8%

Total Debt

$9.66M

-24.7%

Accounts Receivable

$543.00K

-23.8%

Inventory

$0.00

+100.0%

Long Term Debt

$8.71M

-11.5%

Short Term Debt

$950.00K

-68.3%

Return on Assets

-8.47%

N/A

Return on Invested Capital

-13.10%

N/A

Free Cash Flow

-$27.71M

-5.6%

Operating Cash Flow

-$27.69M

-5.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GBTGlobal Blood Therapeutics, Inc.
$68.49+0.01%
RYZBRayzeBio, Inc. Common Stock
$62.49+0.02%
MRTXMirati Therapeutics, Inc.
$58.70-0.17%
CCXIChurchill Capital Corp XI
$13.86-1.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.